Genocea Biosciences’s Therapeutic Vaccine For Herpes Simplex-2 Infection Shows Highly Significant Reductions In Clinical Symptoms At 6 Months

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose. Genocea, a company pioneering novel T cell vaccines and immunotherapies, reported the results from the ongoing trial of GEN-003 today as an oral presentation at the World Vaccine Congress, being held March 24-26 in Washington, DC.

Help employers find you! Check out all the jobs and post your resume.